ArticleCureus2025
Initial Endoscopic Ventricular Failure to Relieve Hydrocephalus in Patients With Obstructing Brain Tumors Predicts a Histone 3K27M Mutation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Diffuse midline gliomas (DMG) are a subset of malignant gliomas that could be linked to an H3K27M mutation. Hydrocephalus may be the initial presenting condition because of its frequent pontine location. This study evaluated the outcomes of tumor resection, endoscopic third ventriculostomy (ETV), and ventriculoperitoneal shunt (VPS) placement in DMG patients compared to wild-type (WT) tumors in treating hydrocephalus. Materials and methods We identified newly diagnosed pediatric and adult patients with midline tumors over an eight-year period (September 14, 2016-July 1, 2024). Results Out of a total of 74 patients, 20 (27.0%) patients were diagnosed with an H3K27M mutation, and 24 (32.4%) presented with hydrocephalus. Patients with a DMG H3K27M mutant (15 patients) were statistically more likely to be diagnosed with hydrocephalus compared to those with a WT midline glioma (9 patients) (p<0.001). Of the 24 patients with hydrocephalus, 8 (34.8%) underwent a VPS placement, 5 (22.7%) had tumor resection, 5 (21.7%) underwent an ETV, and 4 (17.4%) had both a VPS and ETV. A significant difference in hydrocephalus-free survival was observed among the treatment groups (p=0.0013). ETV failure was significantly higher in H3K27M patients while VPS was more successful in managing hydrocephalus. Conclusions As H3K27M mutation analysis is not available rapidly when patients initially present with midline gliomas, neurosurgeons use their best clinical judgment regarding the management of hydrocephalus. VPS demonstrated superior outcomes compared to ETV in controlling hydrocephalus among patients with a DMG H3K27M mutation in the present study; therefore, neurosurgical teams should have increased vigilance following ETV in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.